Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: JOEBT1 who wrote (11357)	11/17/1997 11:48:00 PM
From: Dan O.	Read Replies (1) \| Respond to of 32384

Thanks Joe, if each of those is good for 2 pts we should see 24 by April 1st. I really like your last statement. Most people have disclaimers, not proclamations <g>. You may be setting yourself up for a suite though. Glad your insured. Dan O.

To: JOEBT1 who wrote (11357)	11/17/1997 11:55:00 PM
From: Andrew H	Read Replies (1) \| Respond to of 32384

Thanks, JOE. Did they say anything about Henry's 3 articles? (:>) Targretin for KS is a new one on me. I hadn't heard of that before. Sounds like they might release info on the diabetes trial, which I had given up on. Well, seems like lots of goon news on the way. Hope it hits the wires soon!! Thanks, I feel better. Looks like another nice gain for Japan--3.5% at the moment.

To: JOEBT1 who wrote (11357)	11/17/1997 11:57:00 PM
From: JOEBT1	Read Replies (1) \| Respond to of 32384

Whoops, I meant I can' t insure accuracy because it was based on my notes.Sorry about typo. No guarantees on info in my 11:34 Nov 17 message.

To: JOEBT1 who wrote (11357)	11/18/1997 9:27:00 AM
From: celeryroot.com	Respond to of 32384

I also suspect the arbitrage bandits(meaning the ALRI holders,Farralon) are at work again. I , once again, think it would be in Lgnd's best interest to do a private placement at a premium and pay all cash for ALRI. This would put a little squeeze on them and put the stock into the hands of longer holders.

To: JOEBT1 who wrote (11357)	11/18/1997 12:59:00 PM
From: Henry Niman	Respond to of 32384

JOEBT1, Thanks for the update from IR. Your post has even more than I expected. In addition to the slew of clinicals, the leptin signalling deal, the LLY LGD1268 IND, and the selection of the LLY compound, I expect a good deal more. LGND has announced an IND for TSE424 for 1Q, '98 and I also expect LLY to start US diabetes trials around that time also. I expect AGN to beginn gearing up with an IND for their anti-retinoid as well as INDs for their metabolic disease Rexinoids. A diabetes deal between AGN and one of the big boys who lost their bid to LLY, would not surprise me. I believe that the IND for LGD1268 as well as the start of a US diabetes trial for Targretin will also trigger milestone payments from LLY. I also expect to see the three article I mentioned previously as well as a few initiations of coverage from major brokerage houses. Since we are closing in on the 1 year aniversary of LGND's 1 1/2 month run from 11 1/4 to 17, I expect a repeat, although it should be bigger and better because of the news listed above.

To: JOEBT1 who wrote (11357)	11/18/1997 1:45:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

JOEBT1, Your list of upcoming announcements certainly suggests that LGND's move this year could be significantly stronger than last year, so its probably worth making a comparision between the two years. Last year at the end of August, LGND announced the start of the 3 Phase III clinical trials for treating CTCL with topical or oral Targretin. In September they presented at Bear Stearns and made the announcements that gave birth to this thread, the use of Targretin to prevent and treat breast cancer and type II diabetes. On Sept 25 they announced a secondary and a month later they announced the completion of the offering. In Nov, they just announced 3Q results. This year the recent announcements have been significant. At the end of August, LGND announced the halt of the International Phase III Panretin trial for KS. That was followed by more advanced data on treatment of APL with oral Panretin. Later in September, they announced the splitting up of the ALRT assets, and at the end of the month they announced the impressive data for oral Tragretin treatment of CTCL. On Oct 20, they announced the LLY diabetes deal. I think that a comparision of the press releases a year apart begins to show what kind of progress LGND has made and a comarision between last year's Dec and Jan news compared with news forcasted for the upcoming two months shows what kind of price movement that can be expected.